Have CT-will travel
To boldly go where no scan has gone before In 1962, a new English rock-and-roll band named The Beatles signed a recording contract with Electric & Music Industries (EMI). The Beatles were so financially successful that EMI was able to fund research and development in other divisions of the company, in particular, the work of an enterprising young engineer named Godfrey Hounsfield. His groundbreaking work in x-ray imaging produced the first commercially available head-only CT scanner, and a Nobel Prize.
In 1971, CT scanning entered medical practice in London's Atkinson Morley's Hospital, where the first human CT scan of a left frontal brain tumor was performed. 1 The ability to image the living brain enabled a revolution in understanding brain anatomy and physiology and, in particular, diagnosing ischemic brain injury. Nothing remains more critical to the successful administration of IV thrombolysis than the CT scan.
Over the past nearly 2 decades, major efforts have been made to increase the number of patients treated with IV alteplase 2 and shorten time to treatment, 3 including improving patient triage to designated stroke centers, 4 increasing the efficiency of evaluation and standardization of procedures for acute assessment, 5 and educating prehospital personnel and the public in stroke recognition. When prehospital thrombolysis is used to treat acute myocardial infarction, it requires physicians in the ambulance or emergency medical services (EMS) systems with field EKG transmission capability, paramedic training in EKG interpretation and ST segment elevation myocardial infarction treatment, online medical control, and continuous quality improvement. 6 In the prehospital field, investigators are currently studying the efficacy of neuroprotection therapy within 2 hours of acute stroke onset. 7 Some stroke centers have even reported median thrombolysis administration times of 20 minutes after arrival. 8 In this issue of Neurology ® , Weber et al. 9 propose a radical rethinking of how to dramatically shorten time to stroke thrombolysis. Rather than getting patients evaluated faster in the stroke center, they brought the stroke center to the patient. In the ambulance, they integrated 3 major technical advances-portable CT, mobile broadband, and point-of-care diagnostics-along with adding specialized personnel consisting of a radiology technician and emergency-trained neurologist.
In this preliminary report, out of 152 suspected stroke patients, 45 had strokes and 23 received IV tissue plasminogen activator (tPA). Good recovery occurred in 43% and 2 had symptomatic hemorrhage. Treatment times to thrombolysis were extremely rapid, with a mean call-to-needle time of 62 minutes. This compares favorably with a report 10 of US thrombolysis, in which among 25,504 ischemic stroke patients treated with tPA, doorto-needle time (not call-to-needle) was #60 minutes in only 26.6%, and the International Stroke Thrombolysis Registry (mainly European), in which 11% of patients received tPA within 90 minutes after symptom onset. Though there were some technical failures, they were limited in scope and in affecting clinical outcome. Their proof-of-concept data are intriguing, and the findings suggest a potentially exciting future direction for acute stroke care. However, cautious optimism is warranted until the final results of the full study are available. The key question is whether the stroke emergency mobile unit (STEMO) CT-equipped ambulance paradigm and its favorable results may be replicated elsewhere in Europe and in the United States.
The level of training and experience in the vehicle will be challenging to replicate in a sustainable manner in urban centers, much less in rural areas. Fragmentation in health insurance coverage models, lack of a unified EMS dispatch and response system, and nonuniform broadband access will need to be addressed for successful implementation in other geographic regions. While the telehealth intervention was used only to transmit neuroimages, one can easily imagine extending the telestroke 11 paradigm to provide all the physician and technologist expertise "virtually" to a customary paramedic crew. As mobile broadband networks flourish and software improves, it is only a matter of time before video-enabled interfaces are standard issue and real-time visual and physiologic information is wirelessly transmitted from emergency medical vehicles for medical control. The question is no longer whether these technological advances will be available, but rather how can we best and most costeffectively implement them to improve health outcomes? As long as the number of patients treated by this new model of "ambu-lysis" generates sufficient quality-adjusted life-years at acceptable cost and without dramatic disparities in access to care, adoption is likely to occur.
Without a health authority designating the distribution of advanced stroke centers according to the needs of the population rather than current market forces, unhealthy competition between hospital networks to deploy these "ambu-lysis" vehicles may provide inequitable access to these advanced services. However, some fear that disparities in access to broadband connectivity will increasingly translate into disparities in access to health care. STEMO provokes important social questions about how we address disparities in health care and improve health outcomes as we deploy new technologies.
When Doctor McCoy first entered Star Trek's sick bay, with "tricorders" remotely transmitting critical medical information, few could imagine that we were seeing the future of intensive care. Perhaps in 2050, we will look back at STEMO and reminisce that this was the dawn of a new era in mobile medicine, and that it eventually became the way that the first phase of acute care was delivered.
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